


# PRODUCT INFORMATION



## Sulfinpyrazone

Item No. 17847

**CAS Registry No.:** 57-96-5  
**Formal Name:** 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]-3,5-pyrazolidinedione  
**Synonyms:** G-28315, NSC 75925  
**MF:** C<sub>23</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub>S  
**FW:** 404.5  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 245 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Sulfinpyrazone is supplied as a crystalline solid. A stock solution may be made by dissolving the sulfinpyrazone in the solvent of choice. Sulfinpyrazone is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of sulfinpyrazone in ethanol is approximately 1 mg/ml and approximately 30 mg/ml in DMSO and DMF.

Sulfinpyrazone is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, sulfinpyrazone should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Sulfinpyrazone has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Sulfinpyrazone is a uricosuric agent that competitively inhibits uric acid (Item No. 16219) reabsorption in kidney proximal tubules, which is a key mechanism targeted in the treatment of gout.<sup>1,2</sup> It can also inhibit degranulation of platelets, reducing the release of ADP and thromboxane and diminishing platelet aggregation.<sup>3</sup>

### References

1. Montgomery, D.B. and Ogryzlo, M.A. Comparison of the uricosuric effect of sulfinpyrazone (anturan) and zoxazolamine (flexin). *Can. Med. Assoc. J.* **83**, 885-888 (1960).
2. Underwood, M. Diagnosis and management of gout. *BMJ* **332**, 1315-1319 (2006).
3. Pedersen, A.K. and Jakobsen, P. Sulphinpyrazone metabolism during long-term therapy. *Br. J. Clin. Pharmacol.* **11**, 597-603 (1981).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/04/2023

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM